Regkirona 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification0F
Decision 
Information 
1 issued on 
Issued1F
2 / 
affected2F
3  
amended 
on 
IB/0016 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
24/08/2023 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
IA/0015 
A.7 - Administrative change - Deletion of 
04/05/2023 
n/a 
manufacturing sites 
IB/0012/G 
This was an application for a group of variations. 
24/04/2023 
n/a 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
IA/0013 
A.6 - Administrative change - Change in ATC 
31/03/2023 
SmPC 
Code/ATC Vet Code 
PSUSA/10964
Periodic Safety Update EU Single assessment - 
16/03/2023 
n/a 
PRAC Recommendation - maintenance 
/202208 
regdanvimab (Regkirona) 
IB/0010 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
12/12/2022 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
II/0008 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
10/11/2022 
SmPC 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0009 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
27/10/2022 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
II/0005 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
13/10/2022 
n/a 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/10964
Periodic Safety Update EU Single assessment - 
01/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202202 
regdanvimab (Regkirona) 
IB/0007 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
21/07/2022 
SmPC, 
To update the product information as follows: 
life of the finished product - Biological/immunological 
Labelling and 
- To update Section 6.3 of the SmPC to extend the shelf-life 
medicinal product in accordance with an approved 
PL 
of the finished product from 18 months to 21 months.  
stability protocol 
- To introduce editorial changes including deletion of the QR 
code from Annex III (Labelling, section 18 and Package 
Leaflet, section 6) and to implement linguistic review 
comments from the German and Hungarian health 
authorities. 
II/0004 
Update of section 5.1 of the SmPC to include in vitro 
19/05/2022 
25/05/2022 
SmPC 
In vitro data suggest that the SARS-CoV-2 B.1.1.529 
(Omicron) variant shows reduced susceptibility against 
regdanvimab (Regkirona). 
neutralization activity of regdanvimab against the 
SARS-CoV-2 B.1.1.529 (Omicron) variant of concern 
based on report REP-ND22-047. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0003/G 
This was an application for a group of variations. 
13/04/2022 
25/05/2022 
SmPC 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0002 
B.I.a.2.c - Changes in the manufacturing process of 
24/03/2022 
n/a 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
IB/0001 
To extend the shelf-life of the finished product from 
13/12/2021 
25/05/2022 
SmPC, Annex 
To extend the shelf-life of the finished product from 1 year 
1 year to 15 months when stored at 2°C to 8°C. 
II and PL 
to 15 months when stored at 2°C to 8°C. 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
 
